However, the efficacy of BET inhibitors such as JQ1 in breast cancer therapy is impeded by interleukin-6 (IL-6) through an as-yet-defined mechanism. Methods and results: We investigated the interplay between IL-6 and JQ1 in MCF-7 and MDA-MB-231 human breast cancer cells. The results ...
This may be due to differences in the metabolic requirements of these subtypes of breast cancer. Thus, we might expect that a co-treatment with an anti-glycolytic or pro-OXSPHOS drug (such as metformin) could lead to a synergistic effect and be a promising therapy, especially in TNBC. We...
44 Considering the advancements in cancer therapy, targeted therapy offers a more focused and personalized approach to treating cancer by targeting specific proteins or pathways involved in cancer progression and has evolved strongly after the discovery of JQ1.47, 48, 49, 50 Targeted therapy has adva...
An epigenomic approach to therapy for tamoxifen-resistant breast cancer Cell Res. (2014) L. Togel et al. Dual targeting of bromodomain and extraterminal domain proteins, and WNT or MAPK signaling, inhibits c-MYC expression and proliferation of colorectal cancer cells Mol. Canc. Therapeut. (201...
As a secreted pro-metastatic protein, NID1 has been reported to promote lung metastasis of breast cancer and melanoma35. Zhou et al.20 also showed that NID1 promoted EMT of ovarian cancer cells through activating extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling. Here...
breast cancer; breast conserving surgery; sentinel lymph node biopsy; neoadjuvant therapy; adjuvant therapy 乳腺癌是全球女性最常见的恶性肿瘤,2024年乳腺癌在所有女性的新确诊的病例中占32%,在所有恶性肿瘤中位居第一 〔1〕...
In human epidermal growth factor receptor 2 (HR)-positive breast cancer, anti-HER2 targeted therapies and novel antibody-drug conjugate provide more effective treatment options. However, how to screen the optimal population for dual-targeted the...
Besides suggesting that combinatorial use could be useful therapeutics for the treatment of TNBC, the findings provide a glimpse into potential mechanisms of action for this combination therapy approach.doi:10.1186/s12885-022-09690-2Yellapu, Nanda Kumar...
PARP inhibitors in cancer diagnosis and therapy 2021, Clinical Cancer Research Nanoformulation of PROteolysis TArgeting Chimera targeting ‘undruggable’ c-Myc for the treatment of pancreatic cancer 2020, Nanomedicine The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview 201...
Cancer epigenetics: from mechanism to therapy Cell (2012) M.J.Carrozzaet al. The diverse functions of histone acetyltransferase complexes Trends Genet. (2003) S.H.Baek When signaling kinases meet histones and histone modifiers in the nucleus ...